RIPK3 and central nervous system cancer: Lu et al. [25] reported that shikonin can up-regulate receptor-interacting protein kinase 1 (RIPK1) and receptor-interacting protein kinase 3 (RIPK3) in glioma cells SHG-44, U251, and U87, and increase the production of intracellular reactive oxygen species (ROS).